Trial reportTranslational psychiatry2016
Telomere length as a predictor of response to Pioglitazone in patients with unremitted depression: a preliminary study.
Trial report in Translational psychiatry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 35 citations in OpenAlex.
- Association of Molecular Senescence Markers in Late-Life Depression With Clinical Characteristics and Treatment Outcome.JAMA network open · 2022Trial
- The emergence of chronic diseases of adulthood and middle age in the young: the COIDS (chronic inflammation, obesity, insulin resistance/type 2 diabetes, and depressive syndromes) noxious quartet of pro-inflammatory stress outcomes.Molecular psychiatry · 2025Review
- Valproic Acid and Lamotrigine Differentially Modulate the Telomere Length in Epilepsy Patients.Journal of clinical medicine · 2025Article
- The researcher's guide to selecting biomarkers in mental health studies.BioEssays : news and reviews in molecular, cellular and developmental biology · 2024Review
- Efficacy and Safety of Antidiabetic Agents for Major Depressive Disorder and Bipolar Depression: A Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Trials.Journal of clinical medicine · 2024Article
- Efficacy and acceptability of anti-inflammatory agents in major depressive disorder: a systematic review and meta-analysis.Frontiers in psychiatry · 2024Review
- Cool the Inflamed Brain: A Novel Anti-inflammatory Strategy for the Treatment of Major Depressive Disorder.Current neuropharmacology · 2024Review
- Shorter telomere length predicts poor antidepressant response and poorer cardiometabolic indices in major depression.Scientific reports · 2023Article
- Multidimensional predictors of antidepressant responses: Integrating mitochondrial, genetic, metabolic and environmental factors with clinical outcomes.Neurobiology of stress · 2021Article
- Longer Leukocyte Telomere Length Predicts Stronger Response to a Workplace Sugar-Sweetened Beverage Sales Ban: An Exploratory Study.Current developments in nutrition · 2021Article
- Accelerated brain aging predicts impulsivity and symptom severity in depression.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021Article
- Comparative Efficacy and Acceptability of Anti-inflammatory Agents on Major Depressive Disorder: A Network Meta-Analysis.Frontiers in pharmacology · 2021Article
- Review
- The association of telomere length with substance use disorders: systematic review and meta-analysis protocol.Systematic reviews · 2019Article
- Accelerating research on biological aging and mental health: Current challenges and future directions.Psychoneuroendocrinology · 2019Review
- Review
- Early life adversity blunts responses to pioglitazone in depressed, overweight adults.European psychiatry : the journal of the Association of European Psychiatrists · 2019Article
- Stress, Telomeres, and Psychopathology: Toward a Deeper Understanding of a Triad of Early Aging.Annual review of clinical psychology · 2018Review
- Leukocyte telomere length predicts SSRI response in major depressive disorder: A preliminary report.Molecular neuropsychiatry · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
We studied peripheral leukocyte telomere length (LTL) as a predictor of antidepressant response to PPAR-γ agonist in patients with unremitted depression. In addition we examined correlation between LTL and the insulin resistance (IR) status in these subjects. Forty-two medically stable men and women ages 23-71 with non-remitted depression participated in double-blind placebo-controlled add-on of Pioglitazone to treatment-as-usual. Oral glucose tolerance tests were administered at baseline and at 12 weeks. Diagnostic evaluation of psychiatric disorders was performed at baseline and mood severity was followed weekly throughout the duration of the trial. At baseline, no differences in LTL were detected by depression severity, duration or chronicity. LTL was also not significantly different between insulin-resistant and insulin-sensitive subjects at baseline. Subjects with longer telomeres exhibited greater declines in depression severity in the active arm, but not in a placebo arm, P=0.005, r=-0.63, 95% confidence interval (95% CI)=(-0.84,-0.21). In addition, LTL predicted improvement in insulin sensitivity in the group overall and did not differ between intervention arms, P=0.036, r=-0.44, 95% CI=(-0.74,0.02) for the active arm, and P=0.026, r=-0.50, 95% CI=(-0.78,-0.03) for the placebo arm. LTL may emerge as a viable predictor of antidepressant response. An association between insulin sensitization and LTL regardless of the baseline IR status points to potential role of LTL as a non-specific moderator of metabolic improvement in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.